Europe Liver Cancer Diagnostics Market
Market Size in USD Billion
CAGR :
% 
 Forecast Period |
2023 –2030 |
 Market Size (Base Year) |
USD 1,593.49 Million |
 Market Size (Forecast Year) |
USD 2,533.55 Million |
 CAGR |
% |
| Major Markets Players |
Europe Liver Cancer Diagnostics Market, By Test Type (Imaging Test, Biopsy, Genomic Test, and Others), Cancer Stages (Stage 0, Stage I , Stage II, Stage III, and Stage IV), Cancer Type (Primary Liver Cancer and Secondary Liver Cancer), Product (Platform-Based Products, Instrument Based Products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research), Gender (Female and Male), End-User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others) - Industry Trends and Forecast to 2030.
Europe Liver Cancer Diagnostics Market Analysis and Insights
The Europe liver cancer diagnostics market is expected to grow in the forecast year due to the rise in market players and the availability of advanced services. Along with this, manufacturers are engaged in R&D activity for launching novel services in the market. The growing demand for better quality healthcare for liver cancer and rising preference for preventative health checkups is expected to boost the market’s growth.
However, the high cost of diagnostics procedures and the lack of skilled and certified professionals are expected to challenge market growth.
The Europe liver cancer diagnostics market is expected to gain market growth in the forecast period of 2023 to 2030. Data Bridge Market Research analyses that the market is growing with a CAGR of 6.0% in the forecast period of 2023 to 2030 and is expected to reach USD 2,533.55 Million by 2030 from USD 1,593.49 Million in 2022.
Europe liver cancer diagnostics market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario, contact us for an analyst brief. Our team will help you create a revenue impact solution to achieve your desired goal. The scalability and business expansion of the retail units in the developing countries of various regions and partnership with suppliers for the safe distribution of machine and drug products are the major drivers which propelled the demand of the market in the forecast period.
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customizable to 2015-2020) |
|
Quantitative Units |
Revenue in USD Million |
|
Segments Covered |
By Test Type (Imaging Test, Biopsy, Genomic Test, and Others), Cancer Stages (Stage 0, Stage I , Stage II, Stage III, and Stage IV), Cancer Type (Primary Liver Cancer and Secondary Liver Cancer), Product (Platform-Based Products, Instrument Based Products, Kits and Reagents, and Other Consumables), Technology (Fluorescent In Situ Hybridization, Next Generation Sequencing, Fluorimmunoassay, Comparative Genomic Hybridization, Immunohistochemical, and Others), Application (Screening, Diagnostic and Predictive, Prognostic, and Research), Gender (Female and Male), End-User (Hospitals, Diagnostic Centers, Cancer Research Centers, Academic Institutes, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Retail Sales, and Others) |
|
Countries Covered |
Germany, France, U.K., Italy, Russia, Spain, Netherlands, Switzerland, Norway, Poland, Sweden, Belgium, Turkey, Denmark, Finland, and the Rest of Europe |
|
Market Players Covered |
Siemens Healthcare GmbH (Germany), Koninklijke Philips N.V.(Netherland), Agilent Technologies, Inc. (U.S.), Illumina, Inc. (U.S.), Epigenomics AG (Germany), Tebubio, Thermo Fisher Scientific Inc. (U.S.), QIAGEN(U.S.), F. Hoffmann-La Roche Ltd(Switzerland), Fujirebio(Japan), Diagnostic Biosystems Inc. (U.S.), FUJIFILM Corporation (Japan), MOLGEN (Netherlands), Sysmex Corporation (Japan), Hipro Biotechnology Co., Ltd. (China), Altogen Biosystems (U.S.), ABK Biomedical Inc.(Canada), Diazyme Laboratories, Inc. (U.S.), among others. |
Market Definition
Liver cancer diagnostics refers to the various methods and techniques used to detect and diagnose liver cancer. This may include laboratory tests, imaging tests, and physical examinations.
The liver cancer diagnostic market includes a wide range of products and services from various companies, including diagnostic laboratories, medical device manufacturers, and pharmaceutical companies. The market is driven by the increasing incidence of liver cancer and the growing demand for accurate and reliable diagnostic tests.
Europe Liver Cancer Diagnostics Market Dynamics
Drivers
-
Unmet need for non-invasive, accurate, and reliable diagnostic tests for earlier cancer detection
Diagnostics is also becoming an increasingly important tool for converting the most recent developments in basic research into better clinical outcomes for patients. The development of novel, quick, sensitive, less invasive, and more accurate molecular diagnostic tests is being accelerated by some of the most exciting scientific developments of the time, including genomics, proteomics, and other "omics" technologies. This significantly impacts the ability to identify and treat different cancers earlier and more precisely. By customizing medicines based on each patient's distinct molecular profile, diagnostics help doctors make better-educated treatment decisions.
Thus, the unmet need for non-invasive, accurate, and reliable diagnostic tests for earlier cancer detection demands is expected to drive the market's growth.
-
Increasing early diagnosis of liver cancer
Machine learning could revolutionize early cancer diagnosis, which trains computers to see patterns in complex data. Tools include assessments of common health data, medical imaging, biopsy samples, and blood tests to help in early diagnosis and risk stratification. In many tumor types, the likelihood of undergoing successful therapy increases with an early cancer diagnosis. One important strategy is to assess patients at risk who do not exhibit symptoms and respond quickly and appropriately to those who do.
Thus, earlier detection improves treatment options, patient outcomes, and survival and is expected to drive the growth of the Europe liver cancer diagnostics market.
Restraint
-
Barriers to liver cancer diagnosis and poor prognosis
Cancer is the leading cause of death in developed and developing countries. Cancer mortality is expected to rise to an estimated 13.1 million deaths annually by 2030. However, certain types of cancer have a high chance of being cured if they are detected at an early stage and adequately treated. The delays in cancer diagnosis may occur throughout the diagnostic pathway: patient, primary care, and secondary care. Patient delays may occur when the patient fails to recognize and act on suspicious cancer symptoms. Poor public awareness of early cancer symptoms is considered the predominant reason for delayed presentation, particularly if symptoms are atypical in nature.
The late diagnosis often results from these factors, which result in poor prognosis. Thus, these are expected to restrain the growth of the Europe liver cancer diagnostics market.
Opportunity
-
Increasing awareness towards liver cancer
Liver cancer awareness is a chance to increase knowledge about these diseases and to put the spotlight on research into their causes, prevention, diagnosis, treatment, and survival. The objective is to assist persons who have been impacted by the liver and to promote healthy habits. Primary liver cancer is the name for cancer that develops in the liver. Hepatocellular carcinoma is the most prevalent type of primary liver cancer in adults (HCC). The third most common cause of cancer-related fatalities worldwide is this particular form of liver cancer. About 25,000 men and 11,000 women are diagnosed with liver cancer each year in the US, and the illness claims the lives of 19,000 men and 9,000 women.
Thus, government initiatives toward liver cancer diagnostics is expected to create an opportunity for the growth of the market.
Challenge
- Strict regulations for the approval of liver cancer diagnostic products
The strict guidelines for product approval and market commercialization are proving to be a major obstacle for manufacturers of cancer diagnostic products worldwide. Every nation has its own regulations and employs a different regulating body.
The players involved in the production and marketing of medical devices must adjust as a result of the strict regulations. This would affect all stakeholders globally, which is projected to challenge the market throughout the forecast period. Thus, it is expected to act as a challenge for the Europe liver cancer diagnostics market to hamper its growth.
Recent Development
- In December 2022, FUJIFILM Holdings America Corporation announced the company has a purchase agreement asset with Inspirata, Inc. to acquire a digital pathology business to expand its robust enterprise imaging offering. This results in enabling the integration of pathology images and data into a healthcare organization’s electronic health record system to streamline care delivery for oncology patients
Europe Liver Cancer Diagnostics Market Scope
The Europe liver cancer diagnostics market is categorized into nine notable segments, which are test type, cancer type, cancer stages, product, application, technology, gender, end-user, and distribution channels.
By Test Type
- Imaging Test
- Biopsy
- Genomic Test
- Others
By Cancer Stages
- Stage 0
- Stage I
- Stage II
- Stage III
- Stage IV
By Cancer Type
- Primary Liver Cancer
- Secondary Liver Cancer
By Product
- Platform-Based Products
- Instrument-Based Products
- Kits And Reagents
- Other Consumables
By Technology
- Fluorescent In Situ Hybridization
- Next Generation Sequencing
- Fluoroimmunoassay
- Comparative Genomic Hybridization
- Immunohistochemical
- Others
By Application
- Screening
- Diagnostic And Predictive
- Prognostic
- Research
By Gender
- Female
- Male
By End-User
- Hospitals
- Cancer Research Centers
- Academic Institutes
- Diagnostic Centers
- Ambulatory Surgical Centers
- Others
By Distribution Channel
- Direct Tenders
- Retail Sales
- Others
Europe Liver Cancer Diagnostics Market Regional Analysis/Insights
The Europe liver cancer diagnostics market is segmented into nine notable segments based on test type, cancer stages, cancer type, product, application, technology, gender, end-user, and distribution channel.
The countries covered in this market report are Germany, France, U.K., Italy, Russia, Spain, Netherlands, Switzerland, Norway, Belgium, Turkey, and the Rest of Europe.
Germany is dominating due to a rise in the production of liver cancer diagnostics and increasing demand from emerging markets, and expansion of healthcare industries.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Europe Liver Cancer Diagnostics Market Share Analysis
Europe liver cancer diagnostics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product approvals, product width and breath, application dominance, and technology lifeline curve. The above data points provided are only related to the company’s focus on the Europe Liver cancer diagnostics market.
Some of the major players operating in the Europe liver cancer diagnostics market are Siemens Healthcare GmbH (Germany), Koninklijke Philips N.V.(Netherland), Agilent Technologies, Inc. (U.S.), Illumina, Inc. (U.S.), Epigenomics AG (Germany), Tebubio, Thermo Fisher Scientific Inc. (U.S.), QIAGEN(U.S.), F. Hoffmann-La Roche Ltd(Switzerland), Fujirebio(Japan), Diagnostic Biosystems Inc. (U.S.), FUJIFILM Corporation (Japan), MOLGEN (Netherlands), Sysmex Corporation (Japan), Hipro Biotechnology Co., Ltd. (China), Altogen Biosystems (U.S.), ABK Biomedical Inc.(Canada), and Diazyme Laboratories, Inc. (U.S.) among others.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE EUROPE LIVER CANCER DIAGNOSTICS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 TEST TYPE LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTLE ANALYSIS
4.2 PORTER ANALYSIS
4.3 EPIDEMIOLOGY
5 EUROPE LIVER CANCER DIAGNOSTICS MARKET, REGULATIONS
6 INDUSTRY INSIGHTS
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 UNMET NEED FOR NON-INVASIVE, ACCURATE, AND RELIABLE DIAGNOSTIC TESTS FOR EARLIER CANCER DETECTION
7.1.2 INCREASING EARLY DIAGNOSIS OF LIVER CANCER
7.1.3 INCREASING CASES OF LIVER CANCER
7.1.4 RISE IN DIAGNOSTIC PRODUCT APPROVALS
7.2 RESTRAINTS
7.2.1 BARRIERS TO LIVER CANCER DIAGNOSIS AND POOR PROGNOSIS
7.2.2 HIGH FALSE-POSITIVES AND POOR SENSITIVITY OF LIVER CANCER DIAGNOSIS
7.3 OPPORTUNITIES
7.3.1 INCREASING AWARENESS TOWARDS LIVER CANCER
7.3.2 GOVERNMENT INITIATIVES TOWARD LIVER CANCER DIAGNOSTICS
7.3.3 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE
7.4 CHALLENGES
7.4.1 STRICT REGULATIONS FOR THE APPROVAL OF LIVER CANCER DIAGNOSTIC PRODUCTS
7.4.2 LACK OF SKILLED AND CERTIFIED EXPERTISE
8 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE
8.1 OVERVIEW
8.2 IMAGING TEST
8.2.1 MAGNETIC RESONANCE IMAGING (MRI)
8.2.1.1 MR ANGIOGRAPHY (MRA)
8.2.1.2 MR CHOLANGIOPANCREATOGRAPHY
8.2.2 COMPUTED TOMOGRAPHY
8.2.3 POSITRON EMISSION TOMOGRAPHY
8.2.4 ULTRASOUND
8.2.5 OTHERS
8.3 GENOMIC TEST
8.4 BIOPSY
8.4.1 FINE NEEDLE ASPIRATION BIOPSY
8.4.2 CORE NEEDLE BIOPSY
8.4.3 LAPAROSCOPY
8.5 OTHERS
9 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGE
9.1 OVERVIEW
9.2 STAGE III
9.3 STAGE II
9.4 STAGE IV
9.5 STAGE I
9.6 STAGE 0
10 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE
10.1 OVERVIEW
10.2 SECONDARY LIVER CANCER
10.2.1 HEMANGIOMA
10.2.2 HEPATIC ADENOMA
10.2.3 FOCAL NODULAR HYPERPLASIA
10.3 PRIMARY LIVER CANCER
10.3.1 HEPATOCELLULAR CARCINOMA (HCC)
10.3.2 INTRAHEPATIC CHOLANGIOCARCINOMA (BILE DUCT CANCER)
10.3.3 ANGIOSARCOMA HEMANGIOSARCOMA
10.3.4 HEPATOBLASTOMA
11 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT
11.1 OVERVIEW
11.2 PLATFORM BASED PRODUCTS
11.2.1 NEXT GENERATION SEQUENCING
11.2.2 MICROARRAYS
11.2.3 PCR
11.2.4 OTHERS
11.3 INSTRUMENT BASED PRODUCTS
11.3.1 IMAGING
11.3.2 BIOPSY
11.4 KITS AND REAGENTS
11.4.1 ELISA TEST KITS
11.4.2 CASSETTE TEST KITS
11.4.3 OTHERS
11.5 OTHER CONSUMABLES
12 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION
12.1 OVERVIEW
12.2 SCREENING
12.2.1 PLATFORM BASED PRODUCTS
12.2.2 INSTRUMENT BASED PRODUCTS
12.2.3 KITS AND REAGENTS
12.2.4 OTHER CONSUMABLES
12.3 DIAGNOSTIC AND PREDICTIVE
12.3.1 PLATFORM BASED PRODUCTS
12.3.2 INSTRUMENT BASED PRODUCTS
12.3.3 KITS AND REAGENTS
12.3.4 OTHER CONSUMABLES
12.4 PROGNOSTIC
12.4.1 PLATFORM BASED PRODUCTS
12.4.2 INSTRUMENT BASED PRODUCTS
12.4.3 KITS AND REAGENTS
12.4.4 OTHER CONSUMABLES
12.5 RESEARCH
12.5.1 PLATFORM BASED PRODUCTS
12.5.2 INSTRUMENT BASED PRODUCTS
12.5.3 KITS AND REAGENTS
12.5.4 OTHER CONSUMABLES
13 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY
13.1 OVERVIEW
13.2 FLUORESCENT IN SITU HYBRIDIZATION
13.3 NEXT GENERATION SEQUENCING
13.4 FLUORIMMUNOASSAY
13.5 COMPARATIVE GENOMIC HYBRIDIZATION
13.6 IMMUNOHISTOCHEMICAL
13.7 OTHERS
14 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY GENDER
14.1 OVERVIEW
14.2 MALE
14.3 FEMALE
15 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 DIAGNOSTIC CENTERS
15.4 CANCER RESEARCH CENTERS
15.5 AMBULATORY SURGICAL CENTERS
15.6 ACADEMIC INSTITUTES
15.7 OTHERS
16 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 DIRECT TENDER
16.3 RETAIL SALES
16.4 OTHERS
17 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY REGION
17.1 EUROPE
17.1.1 GERMANY
17.1.2 FRANCE
17.1.3 RUSSIA
17.1.4 ITALY
17.1.5 U.K.
17.1.6 SPAIN
17.1.7 TURKEY
17.1.8 NETHERLANDS
17.1.9 BELGIUM
17.1.10 SWITZERLAND
17.1.11 REST OF EUROPE
18 EUROPE LIVER CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: EUROPE
19 SWOT ANALYSIS
20 COMPANY PROFILE
20.1 F. HOFFMANN-LA ROCHE LTD.
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 COMPANY SHARE ANALYSIS
20.1.4 PRODUCT PORTFOLIO
20.1.5 RECENT DEVELOPMENT
20.2 KONINLIJKE PHILIPS N.V.
20.2.1 COMPANY SNAPSHOT
20.2.2 REVENUE ANALYSIS
20.2.3 COMPANY SHARE ANALYSIS
20.2.4 PRODUCT PORTFOLIO
20.2.5 RECENT DEVELOPMENT
20.3 THERMO FISHER SCIENTIFIC INC.
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE ANALYSIS
20.3.3 COMPANY SHARE ANALYSIS
20.3.4 PRODUCT PORTFOLIO
20.3.5 RECENT DEVELOPMENT
20.4 BD
20.4.1 COMPANY SNAPSHOT
20.4.2 REVENUE ANALYSIS
20.4.3 COMPANY SHARE ANALYSIS
20.4.4 PRODUCT PORTFOLIO
20.4.5 RECENT DEVELOPMENTS
20.5 SIEMENS HEALTHCARE GMBH
20.5.1 COMPANY SNAPSHOT
20.5.2 REVENUE ANALYSIS
20.5.3 COMPANY SHARE ANALYSIS
20.5.4 PRODUCT PORTFOLIO
20.5.5 RECENT DEVELOPMENT
20.6 AGILENT TECHNOLOGIES, INC.
20.6.1 COMPANY SNAPSHOT
20.6.2 REVENUE ANALYSIS
20.6.3 PRODUCT PORTFOLIO
20.6.4 RECENT DEVELOPMENTS
20.7 ABK BIOMEDICAL INC.
20.7.1 COMPANY SNAPSHOT
20.7.2 PRODUCT PORTFOLIO
20.7.3 RECENT DEVELOPMENT
20.8 AB SCIEX PTE LTD. (SUBSIDIARY OF DANAHER.)
20.8.1 COMPANY SNAPSHOT
20.8.2 REVENUE ANALYSIS
20.8.3 PRODUCT PORTFOLIO
20.8.4 RECENT DEVELOPMENT
20.9 ALTOGEN BIOSYSTEMS
20.9.1 COMPANY SNAPSHOT
20.9.2 PRODUCT PORTFOLIO
20.9.3 RECENT DEVELOPMENT
20.1 BIOCEPT, INC.
20.10.1 COMPANY SNAPSHOT
20.10.2 REVENUE ANALYSIS
20.10.3 PRODUCT PORTFOLIO
20.10.4 RECENT DEVELOPMENT
20.11 BODITECH MED INC.
20.11.1 COMPANY SNAPSHOT
20.11.2 PRODUCT PORTFOLIO
20.11.3 RECENT DEVELOPMENTS
20.12 DIAGNOSTIC BIOSYSTEMS INC.
20.12.1 COMPANY SNAPSHOT
20.12.2 PRODUCT PORTFOLIO
20.12.3 RECENT DEVELOPMENT
20.13 DIAZYME LABORATORIES, INC.
20.13.1 COMPANY SNAPSHOT
20.13.2 PRODUCT PORTFOLIO
20.13.3 RECENT DEVELOPMENT
20.14 ELABSCIENCE BIOTECHNOLOGY INC.
20.14.1 COMPANY SNAPSHOT
20.14.2 PRODUCT PORTFOLIO
20.14.3 RECENT DEVELOPMENT
20.15 EPIGENOMICS AG
20.15.1 COMPANY SNAPSHOT
20.15.2 REVENUE ANALYSIS
20.15.3 PRODUCT PORTFOLIO
20.15.4 RECENT DEVELOPMENT
20.16 FUJIFILM CORPORATION
20.16.1 COMPANY SNAPSHOT
20.16.2 REVENUE ANALYSIS
20.16.3 PRODUCT PORTFOLIO
20.16.4 RECENT DEVELOPMENT
20.17 FUJIREBIO
20.17.1 COMPANY SNAPSHOT
20.17.2 PRODUCT PORTFOLIO
20.17.3 RECENT DEVELOPMENTS
20.18 HIPRO BIOTECHNOLOGY CO., LTD.
20.18.1 COMPANY SNAPSHOT
20.18.2 PRODUCT PORTFOLIO
20.18.3 RECENT DEVELOPMENT
20.19 ILLUMINA, INC.
20.19.1 COMPANY SNAPSHOT
20.19.2 REVENUE ANALYSIS
20.19.3 PRODUCT PORTFOLIO
20.19.4 RECENT DEVELOPMENTS
20.2 MOLGEN
20.20.1 COMPANY SNAPSHOT
20.20.2 PRODUCT PORTFOLIO
20.20.3 RECENT DEVELOPMENT
20.21 QIAGEN
20.21.1 COMPANY SNAPSHOT
20.21.2 REVENUE ANALYSIS
20.21.3 PRODUCT PORTFOLIO
20.21.4 RECENT DEVELOPMENT
20.22 Q-LINE BIOTECH PVT LTD.
20.22.1 COMPANY SNAPSHOT
20.22.2 PRODUCT PORTFOLIO
20.22.3 RECENT DEVELOPMENT
20.23 SYSMEX CORPORATION
20.23.1 COMPANY SNAPSHOT
20.23.2 REVENUE ANALYSIS
20.23.3 PRODUCT PORTFOLIO
20.23.4 RECENT DEVELOPMENT
20.24 TEBUBIO
20.24.1 COMPANY SNAPSHOT
20.24.2 PRODUCT PORTFOLIO
20.24.3 RECENT DEVELOPMENT
20.25 TOSOH INDIA PVT. LTD.
20.25.1 COMPANY SNAPSHOT
20.25.2 PRODUCT PORTFOLIO
20.25.3 RECENT DEVELOPMENT
21 QUESTIONNAIRE
22 RELATED REPORTS
List of Table
TABLE 1 DIFFERENT TYPES OF CANCER NON-INVASIVE SCREENING TESTS FOR DIFFERENT TYPES OF CANCERS
TABLE 2 LIVER CANCER RATES
TABLE 3 APPROVED DIAGNOSTICS OF LIVER CANCER
TABLE 4 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 5 EUROPE IMAGING IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 6 EUROPE IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 7 EUROPE MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 8 EUROPE GENETIC TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 9 EUROPE BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 10 EUROPE BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 11 EUROPE OTHERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGE, 2021-2030 (USD MILLION)
TABLE 13 EUROPE STAGE III IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 14 EUROPE STAGE II IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 EUROPE STAGE IV IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 16 EUROPE STAGE I IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 EUROPE STAGE 0 IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 18 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 19 EUROPE SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 EUROPE RENAL CELL CARCINOMA IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 21 EUROPE CLEAR CELL RENAL CELL CARCINOMA IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 EUROPE CLEAR CELL RENAL CELL CARCINOMA IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 23 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 24 EUROPE PLATFORM BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 EUROPE PLATFORM BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 26 EUROPE INSTRUMENT BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 27 EUROPE INSTRUMENT BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 28 EUROPE KITS AND REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 EUROPE KITS AND REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 30 EUROPE OTHER CONSUMABLES IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 31 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 32 EUROPE SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 EUROPE SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 34 EUROPE DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 EUROPE DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 36 EUROPE PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 37 EUROPE PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 38 EUROPE RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 39 EUROPE RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 40 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 41 EUROPE FLUORESCENT IN SITU HYBRIDIZATION IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 EUROPE NEXT GENERATION SEQUENCING IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 EUROPE FLUORIMMUNOASSAY IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 44 EUROPE COMPARATIVE GENOMIC HYBRIDIZATION IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 45 EUROPE IMMUNOHISTOCHEMICAL IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 46 EUROPE OTHERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 47 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 48 EUROPE MALE IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 49 EUROPE FEMALE IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 50 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 51 EUROPE HOSPITALS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 52 EUROPE DIAGNOSTIC CENTERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 53 EUROPE CANCER RESEARCH CENTERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 54 EUROPE AMBULATORY SURGICAL CENTERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 55 EUROPE ACADEMIC INSTITUTES IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 56 EUROPE OTHERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 57 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 58 EUROPE DIRECT TENDER IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 59 EUROPE RETAIL SALES IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 60 EUROPE OTHERS IN LIVER CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 61 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 62 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 63 EUROPE IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 64 EUROPE MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION)
TABLE 65 EUROPE BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 66 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 67 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 68 EUROPE SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 69 EUROPE PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 70 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 71 EUROPE PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 72 EUROPE INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 73 EUROPE KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 74 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 75 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 76 EUROPE SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 77 EUROPE DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 78 EUROPE PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 79 EUROPE RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 80 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 81 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 82 EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 83 GERMANY LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 84 GERMANY IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 85 GERMANY MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION)
TABLE 86 GERMANY BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 87 GERMANY LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 88 GERMANY LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 89 GERMANY SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 90 GERMANY PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 91 GERMANY LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 92 GERMANY PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 93 GERMANY INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 94 GERMANY KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 95 GERMANY LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 96 GERMANY LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 97 GERMANY SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 98 GERMANY DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 99 GERMANY PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 100 GERMANY RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 101 GERMANY LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 102 GERMANY LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 103 GERMANY LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 104 FRANCE LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 105 FRANCE IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 106 FRANCE MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION)
TABLE 107 FRANCE BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 108 FRANCE LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 109 FRANCE LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 110 FRANCE SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 111 FRANCE PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 112 FRANCE LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 113 FRANCE PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 114 FRANCE INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 115 FRANCE KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 116 FRANCE LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 117 FRANCE LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 118 FRANCE SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 119 FRANCE DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 120 FRANCE PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 121 FRANCE RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 122 FRANCE LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 123 FRANCE LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 124 FRANCE LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 125 RUSSIA LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 126 RUSSIA IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 127 RUSSIA MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION)
TABLE 128 RUSSIA BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 129 RUSSIA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 130 RUSSIA LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 131 RUSSIA SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 132 RUSSIA PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 133 RUSSIA LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 134 RUSSIA PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 135 RUSSIA INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 136 RUSSIA KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 137 RUSSIA LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 138 RUSSIA LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 139 RUSSIA SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 140 RUSSIA DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 141 RUSSIA PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 142 RUSSIA RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 143 RUSSIA LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 144 RUSSIA LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 145 RUSSIA LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 146 ITALY LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 147 ITALY IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 148 ITALY MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION)
TABLE 149 ITALY BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 150 ITALY LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 151 ITALY LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 152 ITALY SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 153 ITALY PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 154 ITALY LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 155 ITALY PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 156 ITALY INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 157 ITALY KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 158 ITALY LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 159 ITALY LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 160 ITALY SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 161 ITALY DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 162 ITALY PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 163 ITALY RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 164 ITALY LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 165 ITALY LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 166 ITALY LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 167 U.K. LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 168 U.K. IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 169 U.K. MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION)
TABLE 170 U.K. BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 171 U.K. LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 172 U.K. LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 173 U.K. SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 174 U.K. PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 175 U.K. LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 176 U.K. PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 177 U.K. INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 178 U.K. KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 179 U.K. LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 180 U.K. LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 181 U.K. SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 182 U.K. DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 183 U.K. PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 184 U.K. RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 185 U.K. LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 186 U.K. LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 187 U.K. LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 188 SPAIN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 189 SPAIN IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 190 SPAIN MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION)
TABLE 191 SPAIN BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 192 SPAIN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 193 SPAIN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 194 SPAIN SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 195 SPAIN PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 196 SPAIN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 197 SPAIN PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 198 SPAIN INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 199 SPAIN KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 200 SPAIN LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 201 SPAIN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 202 SPAIN SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 203 SPAIN DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 204 SPAIN PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 205 SPAIN RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 206 SPAIN LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 207 SPAIN LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 208 SPAIN LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 209 TURKEY LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 210 TURKEY IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 211 TURKEY MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION)
TABLE 212 TURKEY BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 213 TURKEY LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 214 TURKEY LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 215 TURKEY SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 216 TURKEY PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 217 TURKEY LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 218 TURKEY PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 219 TURKEY INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 220 TURKEY KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 221 TURKEY LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 222 TURKEY LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 223 TURKEY SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 224 TURKEY DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 225 TURKEY PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 226 TURKEY RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 227 TURKEY LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 228 TURKEY LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 229 TURKEY LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 230 NETHERLANDS LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 231 NETHERLANDS IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 232 NETHERLANDS MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION)
TABLE 233 NETHERLANDS BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 234 NETHERLANDS LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 235 NETHERLANDS LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 236 NETHERLANDS SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 237 NETHERLANDS PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 238 NETHERLANDS LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 239 NETHERLANDS PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 240 NETHERLANDS INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 241 NETHERLANDS KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 242 NETHERLANDS LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 243 NETHERLANDS LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 244 NETHERLANDS SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 245 NETHERLANDS DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 246 NETHERLANDS PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 247 NETHERLANDS RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 248 NETHERLANDS LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 249 NETHERLANDS LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 250 NETHERLANDS LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 251 BELGIUM LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 252 BELGIUM IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 253 BELGIUM MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION)
TABLE 254 BELGIUM BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 255 BELGIUM LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 256 BELGIUM LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 257 BELGIUM SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 258 BELGIUM PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 259 BELGIUM LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 260 BELGIUM PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 261 BELGIUM INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 262 BELGIUM KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 263 BELGIUM LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 264 BELGIUM LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 265 BELGIUM SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 266 BELGIUM DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 267 BELGIUM PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 268 BELGIUM RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 269 BELGIUM LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 270 BELGIUM LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 271 BELGIUM LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 272 SWITZERLAND LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 273 SWITZERLAND IMAGING TEST IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 274 SWITZERLAND MAGNETIC RESONANCE IMAGING (MRI) IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE 2021-2030 (USD MILLION)
TABLE 275 SWITZERLAND BIOPSY IN LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 276 SWITZERLAND LIVER CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 277 SWITZERLAND LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 278 SWITZERLAND SECONDARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 279 SWITZERLAND PRIMARY LIVER CANCER IN LIVER CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 280 SWITZERLAND LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 281 SWITZERLAND PLATFORM-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 282 SWITZERLAND INSTRUMENT-BASED PRODUCTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 283 SWITZERLAND KITS & REAGENTS IN LIVER CANCER DIAGNOSTICS MARKET, BY PRODUCT, 2021-2030 (USD MILLION)
TABLE 284 SWITZERLAND LIVER CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021-2030 (USD MILLION)
TABLE 285 SWITZERLAND LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 286 SWITZERLAND SCREENING IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 287 SWITZERLAND DIAGNOSTIC AND PREDICTIVE IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 288 SWITZERLAND PROGNOSTIC IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 289 SWITZERLAND RESEARCH IN LIVER CANCER DIAGNOSTICS MARKET, BY APPLICATION, 2021-2030 (USD MILLION)
TABLE 290 SWITZERLAND LIVER CANCER DIAGNOSTICS MARKET, BY GENDER, 2021-2030 (USD MILLION)
TABLE 291 SWITZERLAND LIVER CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 292 SWITZERLAND LIVER CANCER DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)
TABLE 293 REST OF EUROPE LIVER CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
List of Figure
FIGURE 1 EUROPE LIVER CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 EUROPE LIVER CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 EUROPE LIVER CANCER DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 EUROPE LIVER CANCER DIAGNOSTICS MARKET: EUROPE VS REGIONAL MARKET ANALYSIS
FIGURE 5 EUROPE LIVER CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 EUROPE LIVER CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 EUROPE LIVER CANCER DIAGNOSTICS MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 EUROPE LIVER CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 EUROPE LIVER CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 EUROPE LIVER CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 11 GROWING AWARENESS OF LIVER CANCER AND INCREASING HEALTHCARE EXPENDITURE ARE EXPECTED TO DRIVE THE GROWTH OF THE EUROPE LIVER CANCER DIAGNOSTICS MARKET FROM 2023 TO 2030
FIGURE 12 THE IMAGING TEST SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE EUROPE LIVER CANCER DIAGNOSTICS MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE EUROPE LIVER CANCER DIAGNOSTICS MARKET
FIGURE 14 THE EUROPE MORTALITY RATE DUE TO CANCER
FIGURE 15 INCREASING EUROPE CANCER RATE IN 2020
FIGURE 16 BARRIERS TO EARLY CANCER DIAGNOSIS AND TREATMENT
FIGURE 17 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022
FIGURE 18 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)
FIGURE 19 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030)
FIGURE 20 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 21 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY CANCER STAGE, 2022
FIGURE 22 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY CANCER STAGE, 2023-2030 (USD MILLION)
FIGURE 23 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY CANCER STAGE, CAGR (2023-2030)
FIGURE 24 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY CANCER STAGE, LIFELINE CURVE
FIGURE 25 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2022
FIGURE 26 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION)
FIGURE 27 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030)
FIGURE 28 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE
FIGURE 29 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY PRODUCT, 2022
FIGURE 30 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY PRODUCT, 2023-2030 (USD MILLION)
FIGURE 31 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY PRODUCT, CAGR (2023-2030)
FIGURE 32 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 33 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY APPLICATION, 2022
FIGURE 34 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY APPLICATION, 2023-2030 (USD MILLION)
FIGURE 35 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY APPLICATION, CAGR (2023-2030)
FIGURE 36 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 37 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, 2022
FIGURE 38 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, 2023-2030 (USD MILLION)
FIGURE 39 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, CAGR (2023-2030)
FIGURE 40 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY TECHNOLOGY, LIFELINE CURVE
FIGURE 41 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY GENDER, 2022
FIGURE 42 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY GENDER, 2023-2030 (USD MILLION)
FIGURE 43 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY GENDER, CAGR (2023-2030)
FIGURE 44 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY GENDER, LIFELINE CURVE
FIGURE 45 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY END USER, 2022
FIGURE 46 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 47 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 48 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE
FIGURE 49 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2022
FIGURE 50 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)
FIGURE 51 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)
FIGURE 52 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 53 EUROPE LIVER CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 54 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 55 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 56 EUROPE LIVER CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 57 EUROPE LIVER CANCER DIAGNOSTICS MARKET: PRODUCT TYPE (2023-2030)
FIGURE 58 EUROPE LIVER CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
